Pakistan’s Pharmaceutical Exports Touch 34% Growth in FY25, 20-Year High
The pharmaceutical industry of Pakistan has been showcasing impressive growth, with the country’s pharmaceutical exports registering a 34% growth during the financial year that was ended on June 30, 2025. The growth has taken the overall value of pharmaceutical exports to $457 million, representing the highest growth in two decades.
Last year, pharmaceutical exports were at $341 million, and this year’s increase is the highest since 2009, when the country’s exports increased by 32%. The pharmaceutical sector is now among the nation’s top-growing export industries.
Aside from pharmaceutical products, other therapeutic items like surgical products, food supplements, medical devices, and nutraceuticals also recorded high export figures. Together, the export value for these items amounted to $909 million in FY25, a little short of the $1 billion mark.
The Pakistan Pharmaceutical Manufacturers’ Association (PPMA) attributed the high growth to positive government price policies. In particular, February 2024 deregulation of non-essential drugs enabled drug companies to concentrate more on exports. The policy also permitted the companies to better manage inflation, streamline production, and decrease the effect of black-market sales.
This deregulation has additionally brought more foreign pharma investment, which has helped to have a good prognosis for the long-term stability of the Pakistan pharmaceutical market.
